Loading...
Market
Which pharmaceutical company will be most affected by the Medicare drug price cuts in terms of revenue loss?
2
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Company financial reports, industry analysis, and news reports
Story
Biden Administration Secures Medicare Drug Price Cuts, Saving $6 Billion
Aug 15, 2024, 06:16 PM
The Biden administration has successfully negotiated price reductions for 10 of the most expensive drugs covered by Medicare, marking a historic first for the program. These negotiations are expected to save Medicare $6 billion in 2026, with enrollees saving $1.5 billion in out-of-pocket costs. The price cuts, ranging from 38% to 79%, are part of the Inflation Reduction Act's provisions aimed at reducing healthcare costs for seniors. The selected drugs, which cost $50 billion yearly, are used to treat conditions such as cancer, heart disease, and diabetes, benefiting approximately 9 million seniors in the United States. This initiative underscores the administration's commitment to tackling high drug prices and easing the financial burden on older Americans.
View original story
Similar markets
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck & Co. • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
CVS • 25%
UNH • 25%
CI • 25%
Other • 25%
Drug A • 25%
Drug B • 25%
Drug C • 25%
Other • 25%
Drug A • 25%
Drug B • 25%
Drug C • 25%
Other • 25%
Eliquis • 25%
Jardiance • 25%
Xarelto • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Eliquis • 25%
Jardiance • 25%
Xarelto • 25%
Other • 25%
CVS Caremark • 33%
Express Scripts • 33%
Other PBM • 33%
CVS • 25%
UNH • 25%
CI • 25%
Other • 25%